Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells 4,045 Shares of Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,045 shares of the stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $20.81, for a total transaction of $84,176.45. Following the sale, the chief financial officer directly owned 105,798 shares of the company’s stock, valued at approximately $2,201,656.38. The trade was a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Neurogene Stock Down 2.3%

Shares of Neurogene stock traded down $0.49 on Tuesday, reaching $21.08. The stock had a trading volume of 112,066 shares, compared to its average volume of 166,384. The company has a 50 day moving average price of $19.11 and a 200 day moving average price of $21.63. Neurogene Inc. has a 1 year low of $6.88 and a 1 year high of $37.27. The stock has a market capitalization of $326.53 million, a P/E ratio of -5.13 and a beta of 1.53.

Institutional Investors Weigh In On Neurogene

A number of large investors have recently made changes to their positions in NGNE. BNP Paribas Financial Markets increased its position in shares of Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after acquiring an additional 978 shares during the period. Daiwa Securities Group Inc. acquired a new stake in Neurogene during the 4th quarter worth about $66,000. PNC Financial Services Group Inc. grew its stake in Neurogene by 43.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock valued at $61,000 after purchasing an additional 1,232 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after purchasing an additional 1,059 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Neurogene in the fourth quarter valued at about $165,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on NGNE shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. Wall Street Zen lowered Neurogene from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Neurogene in a research note on Tuesday, January 13th. Lifesci Capital began coverage on Neurogene in a research report on Monday, January 26th. They set an “outperform” rating and a $50.00 target price on the stock. Finally, Canaccord Genuity Group started coverage on Neurogene in a research note on Friday, February 27th. They issued a “buy” rating for the company. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.